155 related articles for article (PubMed ID: 25171862)
1. A commonly used Drosophila model of Alzheimer's disease generates an aberrant species of amyloid-β with an additional N-terminal glutamine residue.
Allan K; Perez KA; Barnham KJ; Camakaris J; Burke R
FEBS Lett; 2014 Oct; 588(20):3739-43. PubMed ID: 25171862
[TBL] [Abstract][Full Text] [Related]
2. Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer's disease.
Portelius E; Olsson M; Brinkmalm G; Rüetschi U; Mattsson N; Andreasson U; Gobom J; Brinkmalm A; Hölttä M; Blennow K; Zetterberg H
J Alzheimers Dis; 2013; 33(1):85-93. PubMed ID: 22886024
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease.
Iijima K; Liu HP; Chiang AS; Hearn SA; Konsolaki M; Zhong Y
Proc Natl Acad Sci U S A; 2004 Apr; 101(17):6623-8. PubMed ID: 15069204
[TBL] [Abstract][Full Text] [Related]
4. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
6. The Arctic amyloid-β precursor protein (AβPP) mutation results in distinct plaques and accumulation of N- and C-truncated Aβ.
Philipson O; Lord A; Lalowski M; Soliymani R; Baumann M; Thyberg J; Bogdanovic N; Olofsson T; Tjernberg LO; Ingelsson M; Lannfelt L; Kalimo H; Nilsson LN
Neurobiol Aging; 2012 May; 33(5):1010.e1-13. PubMed ID: 22118948
[TBL] [Abstract][Full Text] [Related]
7. pGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity.
Sofola-Adesakin O; Khericha M; Snoeren I; Tsuda L; Partridge L
Acta Neuropathol Commun; 2016 Oct; 4(1):109. PubMed ID: 27717375
[TBL] [Abstract][Full Text] [Related]
8. Structural heterogeneity in familial Alzheimer's disease mutants of amyloid-beta peptides.
Chong SH; Yim J; Ham S
Mol Biosyst; 2013 May; 9(5):997-1003. PubMed ID: 23358498
[TBL] [Abstract][Full Text] [Related]
9. Low-n oligomers as therapeutic targets of Alzheimer's disease.
Ono K; Yamada M
J Neurochem; 2011 Apr; 117(1):19-28. PubMed ID: 21244429
[TBL] [Abstract][Full Text] [Related]
10. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease.
Crowther DC; Kinghorn KJ; Miranda E; Page R; Curry JA; Duthie FA; Gubb DC; Lomas DA
Neuroscience; 2005; 132(1):123-35. PubMed ID: 15780472
[TBL] [Abstract][Full Text] [Related]
11. Studies on the mechanism of the DNA nicking property of amyloid-β40: implications in Alzheimer's disease.
Gupta VB; Monica FS; Berrocal R; Rao KS; Rao KS
J Alzheimers Dis; 2013; 33(4):1059-71. PubMed ID: 23160010
[TBL] [Abstract][Full Text] [Related]
12. Systematic Aβ Analysis in Drosophila Reveals High Toxicity for the 1-42, 3-42 and 11-42 Peptides, and Emphasizes N- and C-Terminal Residues.
Jonson M; Pokrzywa M; Starkenberg A; Hammarstrom P; Thor S
PLoS One; 2015; 10(7):e0133272. PubMed ID: 26208119
[TBL] [Abstract][Full Text] [Related]
13. Modeling the binding mechanism of Alzheimer's Aβ1-42 to nicotinic acetylcholine receptors based on similarity with snake α-neurotoxins.
Maatuk N; Samson AO
Neurotoxicology; 2013 Jan; 34():236-42. PubMed ID: 23022323
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease and the amyloid β-protein.
Walsh DM; Teplow DB
Prog Mol Biol Transl Sci; 2012; 107():101-24. PubMed ID: 22482449
[TBL] [Abstract][Full Text] [Related]
15. Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer's Abeta42 peptide.
Kim W; Hecht MH
Proc Natl Acad Sci U S A; 2006 Oct; 103(43):15824-9. PubMed ID: 17038501
[TBL] [Abstract][Full Text] [Related]
16. Familial Alzheimer A2 V mutation reduces the intrinsic disorder and completely changes the free energy landscape of the Aβ1-28 monomer.
Nguyen PH; Tarus B; Derreumaux P
J Phys Chem B; 2014 Jan; 118(2):501-10. PubMed ID: 24372615
[TBL] [Abstract][Full Text] [Related]
17. Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice.
Härtig W; Goldhammer S; Bauer U; Wegner F; Wirths O; Bayer TA; Grosche J
J Chem Neuroanat; 2010 Sep; 40(1):82-92. PubMed ID: 20347032
[TBL] [Abstract][Full Text] [Related]
18. A new class of aggregation inhibitor of amyloid-β peptide based on an O-acyl isopeptide.
Kawashima H; Sohma Y; Nakanishi T; Kitamura H; Mukai H; Yamashita M; Akaji K; Kiso Y
Bioorg Med Chem; 2013 Nov; 21(21):6323-7. PubMed ID: 24076366
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's disease amyloid β-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils.
Poduslo JF; Howell KG; Olson NC; Ramirez-Alvarado M; Kandimalla KK
Biochemistry; 2012 May; 51(19):3993-4003. PubMed ID: 22545812
[TBL] [Abstract][Full Text] [Related]
20. N-Terminal Hypothesis for Alzheimer's Disease.
Murray B; Sharma B; Belfort G
ACS Chem Neurosci; 2017 Mar; 8(3):432-434. PubMed ID: 28186729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
